Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2022 Dec 23;26(1):194–200. doi: 10.1038/s41391-022-00636-0

Figure 2:

Figure 2:

PSA progression-free survival (PSA PFS), clinical/radiographic PFS, and overall survival (OS). Data are presented for the intent-to-treat cohort (A) and for response-evaluable cohort (B) stratified by presence/absence of a homologous recombination repair (HRR) gene mutation (i.e. HRR deficient/intact). Median PSA PFS was 5 (95% CI 4–21) months for HRR-intact and 9 (95% CI 8-NR) months for HRR-deficient, median clinical/radiographic PFS was 14 (95% CI 13-NR) months for HRR intact and 8 (95% CI 5-NR) for HRR deficient, and median OS was NR (95% CI 26-NR) months for HRR-intact and 25 (95% CI 19-NR) for HRR-deficient.